

## Delay in Lodgement of Appendix 4D and Half-Year Report for the Half-Year Ended 31st December 2023

**Sydney, Australia – 29 February 2024:** Cannabis focused drug development and product innovation company Bod Science Limited (Administrators Appointed) ("Bod" or "Company") (ASX: BOD) advises that its Appendix 4D and Half-Year Report for the half-year ended 31<sup>st</sup> December 2023 will not be lodged by today's deadline.

On 20<sup>th</sup> February 2024, Bod's auditor, Nexia Sydney Audit Pty Ltd, lodged an application with ASIC to resign as the Company's auditor due to a perceived conflict of interest.

In.Corp Audit & Assurance Pty Ltd has advised the Company that it is prepared to accept the appointment as auditor to Bod and on 20<sup>th</sup> February 2024, In.Corp Audit & Assurance Pty Ltd was appointed as the Company's auditor, subject to the consent of ASIC.

The Company, former auditor and new auditor are awaiting upon ASIC approval before the review for the half-year ended 31<sup>st</sup> December 2023 can commence. The ASIC form 342 was lodged with ASIC on 21<sup>st</sup> February 2024 and a response is expected within two to three weeks of that date.

It is expected that the Appendix 4D and Half-Year Report for the half-year ended 31<sup>st</sup> December 2023 will be lodged with the ASX by 28<sup>th</sup> March 2024, dependent upon receiving ASIC consent within the expected timeframe.

This announcement has been approved by the administrator of Bod Science Limited (under administration).

-ENDS-

## **About Bod Science:**

Bod Science Limited (Administrators Appointed) (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson Chief Executive Officer Info@bodaustralia.com +61 2 9199 5018

